Compare Invesco S&P 500 Low Volatility ETF (SPLV) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Low Volatility ETF vs Stryker Corporation — how do they compare? Invesco S&P 500 Low Volatility ETF trades at $72.14 (market cap $6.94B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 15.3× Invesco S&P 500 Low Volatility ETF's market cap, and Stryker Corporation pays a 1.27% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 Low Volatility ETF for 123 Days and Stryker Corporation for 21 Days on average.
| SPLV | SYK | |
|---|---|---|
Market Cap | $6.94B | $106.24B |
Volume | 1,663,703 | 2,982,001 |
52-Week High | $77.97 | $388.35 |
52-Week Low | $70.30 | $269.75 |
Typical Hold Time | 123 Days | 21 Days |
Sector | — | Health |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPLV trades at $71.97, up 1.05% today, but faces bearish technical signals with moving averages indicating selling pressure. The ETF's sector allocation to Utilities, Real Estate, and Financials has caused it to lag the S&P 500's performance. Recent dividend payments of $0.14 per share were distributed in July and September 2026.
The outlook remains neutral with valuation concerns at a 19.5x P/E ratio. Key risks include sector concentration and macroeconomic sensitivity, while potential stability during market volatility offers defensive appeal. Current technical support sits at $70 with resistance at $73.
Stryker (SYK) trades at $276.97, up 0.57% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 64.98% gross margins and 14.43% net income margin, though recent Q1 2026 earnings missed expectations. Analyst consensus remains strongly bullish with 71% buy ratings and $368.11 price target, representing 33% upside potential. Recent news highlights ongoing legal investigations regarding manufacturing issues that caused an 8.8% stock drop in September 2026.
SYK presents a compelling investment case with robust fundamentals and strong analyst support, though near-term headwinds from legal scrutiny and manufacturing challenges create uncertainty. The stock's current valuation at 28.7 P/E appears reasonable given growth prospects, but investors should monitor Q3 2026 earnings results on October 29 for confirmation of business recovery from recent setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
